Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $824.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lifted by Leerink Partners from $641.00 to $824.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has a market perform rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the company. Cantor Fitzgerald upped their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Truist Financial raised their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Barclays decreased their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Finally, HSBC dropped their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $801.70.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $840.84 on Monday. The firm has a market capitalization of $86.57 billion, a price-to-earnings ratio of 20.78, a PEG ratio of 1.38 and a beta of 0.22. The firm’s fifty day simple moving average is $688.35 and its 200-day simple moving average is $715.30. Regeneron Pharmaceuticals has a twelve month low of $541.00 and a twelve month high of $844.92. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $12.81 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at approximately $482,400. The trade was a 39.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,400 shares of company stock worth $1,090,030. 6.97% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Flputnam Investment Management Co. raised its holdings in shares of Regeneron Pharmaceuticals by 106.8% in the second quarter. Flputnam Investment Management Co. now owns 939 shares of the biopharmaceutical company’s stock valued at $586,000 after buying an additional 485 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Regeneron Pharmaceuticals by 25.9% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 5,101 shares of the biopharmaceutical company’s stock worth $3,180,000 after buying an additional 1,048 shares during the last quarter. Greenwood Capital Associates LLC grew its holdings in shares of Regeneron Pharmaceuticals by 23.2% during the second quarter. Greenwood Capital Associates LLC now owns 13,873 shares of the biopharmaceutical company’s stock worth $8,650,000 after buying an additional 2,612 shares during the last quarter. New Mexico Educational Retirement Board grew its holdings in shares of Regeneron Pharmaceuticals by 4.2% during the second quarter. New Mexico Educational Retirement Board now owns 5,000 shares of the biopharmaceutical company’s stock worth $3,118,000 after buying an additional 200 shares during the last quarter. Finally, Mufg Securities Americas Inc. increased its position in Regeneron Pharmaceuticals by 7.9% in the 2nd quarter. Mufg Securities Americas Inc. now owns 3,010 shares of the biopharmaceutical company’s stock valued at $1,877,000 after acquiring an additional 221 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru as the first and only treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare disorder involving abnormal bone formation in soft tissues. In the placebo-controlled OPTIMA trial, Pasatru reduced new heterotopic ossification lesions by at least 90% at 56 weeks and significantly reduced clinician-assessed flare-ups. The approval adds a potential commercial product and strengthens Regeneron’s rare-disease portfolio. Reuters FDA approval article
• Positive Sentiment: The Pasatru approval is supported by meaningful clinical efficacy in a condition with limited treatment options, potentially giving Regeneron pricing and market-entry advantages in a highly specialized market. The financial contribution may initially be limited by FOP’s very small patient population, but the regulatory milestone can improve long-term pipeline value. Pasatru approval announcement
• Neutral Sentiment: Regeneron announced upcoming investor conference presentations by management. The events could provide additional details on Pasatru’s launch, the broader pipeline and financial outlook, but the announcement itself does not change current earnings expectations. Regeneron investor conference announcement
• Positive Sentiment: Leerink Partners raised its price target for REGN to $824, signaling continued analyst support for the shares, although the target may not fully reflect the latest trading level. Leerink Partners price target article
• Negative Sentiment: Several law firms publicized securities class actions and a September 14, 2026 lead-plaintiff deadline concerning allegations that Regeneron misrepresented risks surrounding the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, creating litigation costs, reputational risk and uncertainty around the oncology pipeline. These notices largely repeat the same underlying allegations rather than represent new operational developments. Regeneron class action notice

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.